Signaling Pathway Inhibitors, miRNA, and Nanocarrier-Based Pharmacotherapeutics for the Treatment of Lung Cancer: A Review

Abstract

Lung cancer is one of the most commonly diagnosed cancers and is responsible for a large number of deaths worldwide. The pathogenic mechanism of lung cancer is complex and multifactorial in origin. Thus, various signaling pathways as targets for therapy are being examined, and many new drugs are in the pipeline. However, both conventional and target-based drugs have been reported to present significant adverse effects, and both types of drugs can affect the clinical outcome in addition to patient quality of life. Recently, miRNA has been identified as a promising target for lung cancer treatment. Therefore, miRNA mimics, oncomiRs, or miRNA suppressors have been developed and studied for possible anticancer effects. However, these miRNAs also suffer from the limitations of low stability, biodegradation, thermal instability, and other issues. Thus, nanocarrier-based drug delivery for the chemotherapeutic drug delivery in addition to miRNA-based systems have been developed so that existing limitations can be resolved, and enhanced therapeutic outcomes can be achieved. Thus, this review discusses lung cancer’s molecular mechanism, currently approved drugs, and their adverse effects. We also discuss miRNA biosynthesis and pathogenetic role, highlight pre-clinical and clinical evidence for use of miRNA in cancer therapy, and discussed limitations of this therapy. Furthermore, nanocarrier-based drug delivery systems to deliver chemotherapeutic drugs and miRNAs are described in detail. In brief, the present review describes the mechanism and up-to-date possible therapeutic approaches for lung cancer treatment and emphasizes future prospects to bring these novel approaches from bench to bedside.

Mimic miRNA and Anti-miRNA Activated Scaffolds as a Therapeutic Strategy to Promote Bone, Cartilage, and Skin Regeneration

“…In addition, unmodified free anti-miRNAs and mimic miRNAs are rapidly degraded and eliminated in the bloodstream by numerous nucleases [55]. Finally, miRNAs can be immunotoxic by activating interferons or Toll-like receptors (TLRs) [56] and neurotoxic by inducing neurodegeneration through TLRs [57,58].…”

A Functional Genomics Review of Non-Small-Cell Lung Cancer in Never Smokers

“…Nevertheless, durable responses to ICI have not been successful in all cancers, as a number of cancers were more efficiently 'hidden' from host immune surveillance than others, or so-called immune 'silent/cold'. A number of signalling pathways are being examined as therapeutic targets; however, both conventional and targeted drugs have unfortunately presented significant adverse effects [12]. In fact, current or former NSCLC smokers receiving anti-PD-1 therapy achieved a response rate of 22.5%, almost double that in NS (10.3%).…”

Applications of Nonviral Biomaterials for microRNA Transfection in Bone Tissue Engineering

“…Second, unmodified miRNA antagonists and miRNA mimics are rapidly degraded and eliminated in the blood circulation by nucleases that are rich in the patient bloodstream (Grixti et al, 2021). Third, miRNAs can lead to immunotoxicity by activating interferons or Toll-like receptors (Md et al, 2021) and neurotoxicity by triggering neurodegeneration through Toll-like receptors (Chen Y. et al, 2015). Therefore, it is necessary to use a suitable carrier to deliver miRNAs to protect them from inactivation in the process of matrix formation, storage, and release.…”